US Company Enters Crypto with This Altcoin: Launched a $100 Million Strategy!

US-based MEI Pharma has stepped into the crypto world with an investment in Litecoin (LTC) and has initiated a strategy to create a $100 million corporate treasury.

The pharmaceutical company MEI Pharma, which develops cancer treatments, has made a significant leap from the traditional finance world to the cryptocurrency sector. The company announced that it would invest $100 million in Litecoin (LTC) in collaboration with Titan Partners Group, one of the major investment institutions in the US, and the crypto investment firm GSR. Following this development, MEIP shares quickly rose from $4.20 to $11.45, but then experienced a rapid decline, falling to $6.

Charlie Lee, the creator of Litecoin, will also join MEI Pharma's board of directors, providing significant vision and leadership to the company. Additionally, the Litecoin Foundation, which aims to promote the adoption of Litecoin globally, has also invested in MEI Pharma.

The participation of Charlie Lee, who has become one of the most respected figures in the crypto world since he created Litecoin in 2011, is seen as an exciting development for the crypto sector. In his statement, Lee said, “Litecoin has been providing millions of users with a reliable, low-cost, and accessible payment network for 14 years. With this partnership, we will leverage the advantages that Litecoin offers in the corporate sector for the first time.”

Litecoin is widely preferred for cross-border transactions, retail payments, and money transfers, especially on platforms like BitPay. Charlie Lee, a key figure behind Litecoin's success, has also been a pioneer of the SegWit upgrade and ensured that this innovation was also adopted by Bitcoin (BTC).

MEI Pharma's bold move is considered an important step to strengthen Litecoin's position in the corporate world.